1-12 of 12
rivaroxaban
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Effectiveness and safety of rivaroxaban compared with low-molecular-weight heparin in cancer-associated thromboembolism

Clinical Trials & Observations
Olivia S. Costa, Christine G. Kohn, Nicole M. Kuderer, Gary H. Lyman, Thomas J. Bunz, Craig I. Coleman
Journal: Blood Advances
Blood Adv (2020) 4 (17): 4045–4051.
https://doi.org/10.1182/bloodadvances.2020002242
Published: 2020
Journal Articles

An engineered factor Va prevents bleeding induced by direct-acting oral anticoagulants by different mechanisms

Annette von Drygalski, Vikas Bhat, Andrew J. Gale, Patricia M. Averell, Thomas J. Cramer, Darlene J. Elias, John H. Griffin, Laurent O. Mosnier
Journal: Blood Advances
Blood Adv (2020) 4 (15): 3716–3727.
https://doi.org/10.1182/bloodadvances.2020001699
Published: 2020
Includes: Supplemental data
Journal Articles

Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure

Clinical Trials & Observations
Joseph R. Shaw, Na Li, Thomas Vanassche, Michiel Coppens, Alex C. Spyropoulos, Summer Syed, Mansoor Radwi, Joanne Duncan, Sam Schulman, James D. Douketis
Journal: Blood Advances
Blood Adv (2020) 4 (15): 3520–3527.
https://doi.org/10.1182/bloodadvances.2020002335
Published: 2020
Includes: Supplemental data
Journal Articles

Safety and feasibility of rivaroxaban in deferred workup of patients with suspected deep vein thrombosis

Clinical Trials & Observations
Synne G. Fronas, Anders E. A. Dahm, Hilde S. Wik, Camilla T. Jørgensen, Jostein Gleditsch, Nezar Raouf, René Holst, Frederikus A. Klok, Waleed Ghanima
Journal: Blood Advances
Blood Adv (2020) 4 (11): 2468–2476.
https://doi.org/10.1182/bloodadvances.2020001556
Published: 2020
Journal Articles

A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers

Clinical Trials & Observations
Genmin Lu, Pamela B. Conley, Janet M. Leeds, Mark J. Karbarz, Gallia G. Levy, Vandana S. Mathur, Janice Castillo, Mark Crowther, John T. Curnutte
Journal: Blood Advances
Blood Adv (2020) 4 (4): 728–739.
https://doi.org/10.1182/bloodadvances.2019000885
Published: 2020
Includes: Supplemental data
Journal Articles

Systematic review and meta-analysis of the efficacy and safety of apixaban compared to rivaroxaban in acute VTE in the real world

Madan Raj Aryal, Rohit Gosain, Anthony Donato, Han Yu, Anjan Katel, Yashoda Bhandari, Rashmi Dhital, Peter A. Kouides
Journal: Blood Advances
Blood Adv (2019) 3 (15): 2381–2387.
https://doi.org/10.1182/bloodadvances.2019000572
Published: 2019
Includes: Supplemental data
Journal Articles

Comparison of reversal activity and mechanism of action of UHRA, andexanet, and PER977 on heparin and oral FXa inhibitors

Manu T. Kalathottukaren, A. Louise Creagh, Srinivas Abbina, Genmin Lu, Mark J. Karbarz, Anjali Pandey, Pamela B. Conley, Jayachandran N. Kizhakkedathu, Charles Haynes
Journal: Blood Advances
Blood Adv (2018) 2 (16): 2104–2114.
https://doi.org/10.1182/bloodadvances.2016003616
Published: 2018
Includes: Supplemental data
Journal Articles

Model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients

Clinical Trials & Observations
Hideki Yoshioka, Hiromi Sato, Hiroto Hatakeyama, Akihiro Hisaka
Journal: Blood Advances
Blood Adv (2018) 2 (10): 1066–1075.
https://doi.org/10.1182/bloodadvances.2017013805
Published: 2018
Includes: Supplemental data
Journal Articles

Risk of recurrent venous thromboembolism according to baseline risk factor profiles

Clinical Trials & Observations
Martin H. Prins, Anthonie W. A. Lensing, Paolo Prandoni, Philip S. Wells, Peter Verhamme, Jan Beyer-Westendorf, Rupert Bauersachs, Henri Bounameaux, Timothy A. Brighton, Alexander T. Cohen, Bruce L. Davidson, Hervé Decousus, Ajay K. Kakkar, Bonno van Bellen, Akos F. Pap, Martin Homering, Miriam Tamm, Jeffrey I. Weitz
Journal: Blood Advances
Blood Adv (2018) 2 (7): 788–796.
https://doi.org/10.1182/bloodadvances.2018017160
Published: 2018
Includes: Supplemental data
Journal Articles

Inhibitory mechanisms of very low–dose rivaroxaban in non–ST-elevation myocardial infarction

Clinical Trials & Observations
Oliver Borst, Patrick Münzer, Nada Alnaggar, Sascha Geue, Roland Tegtmeyer, Dominik Rath, Michal Droppa, Peter Seizer, Stefan Heitmeier, Johan W. M. Heemskerk, Lisa K. Jennings, Robert F. Storey, Dominick J. Angiolillo, Bianca Rocca, Henri Spronk, Hugo Ten Cate, Meinrad Gawaz, Tobias Geisler
Journal: Blood Advances
Blood Adv (2018) 2 (6): 715–730.
https://doi.org/10.1182/bloodadvances.2017013573
Published: 2018
Includes: Supplemental data
Journal Articles

Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation

Clinical Trials & Observations
Surbhi Shah, Faye L. Norby, Yvonne H. Datta, Pamela L. Lutsey, Richard F. MacLehose, Lin Y. Chen, Alvaro Alonso
Journal: Blood Advances
Blood Adv (2018) 2 (3): 200–209.
https://doi.org/10.1182/bloodadvances.2017010694
Published: 2018
Includes: Supplemental data
Journal Articles

Rivaroxaban dose adjustment using thrombin generation in severe congenital protein C deficiency and warfarin-induced skin necrosis

Clinical Trials & Observations
Neethu Menon, Ravi Sarode, Ayesha Zia
Journal: Blood Advances
Blood Adv (2018) 2 (2): 142–145.
https://doi.org/10.1182/bloodadvances.2017012047
Published: 2018
Includes: Supplemental data